RLYBHealthcare · BiotechnologyRLYB Stock Forecast: Rallybio Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 21 Aug 2026 — in the upper half.
RLYB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Rallybio Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (100): The shares have been drifting up relative to others.
Value (16): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
RLYB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RLYB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Apr 2025 | Jones Trading | Downgrade | Hold | — |
| 9 Apr 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Aug 2024 | Evercore ISI Group | Maintains | Outperform | — |
| 12 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2024 | JP Morgan | Downgrade | Neutral | — |
| 10 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Apr 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 18 Apr 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 11 Apr 2024 | Wedbush | Maintains | Outperform | — |
| 13 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Mar 2024 | JMP Securities | Reiterates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RLYB appears on the weeks it earns a place.
RLYB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Rallybio Corp. (RLYB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 2.1×
- Price / sales
- 138.4×
- Price / book
- 1.8×
- EV / EBITDA
- 0.2×
Cheaper than 70% of US stocks
Cheaper than 4% of US stocks
Cheaper than 50% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- −100.0%
- Gross margin
- —
- Operating margin
- −3935.4%
- Net margin
- 7051.2%
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 99% of US stocks
- Return on equity
- 64.9%
- Return on assets
- −21.3%
- Dividend yield
- —
Higher than 94% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
RLYB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rallybio Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about RLYB stock
Is RLYB stock a buy right now?
Of the 1 analysts covering Rallybio Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rallybio Corp. 59 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RLYB?
As at 21 Aug 2026, Rallybio Corp. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).
What is the RLYB stock forecast for 2030?
No analyst covering Rallybio Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLYB are extrapolating price history, which says nothing about the business.
How has RLYB stock performed over the past year?
Rallybio Corp. returned +254.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Rallybio Corp. do?
Rallybio Corporation is a clinical-stage biotechnology company focused on developing and commercializing therapies for patients with severe and rare diseases. The company concentrates on areas of maternal-fetal health, complement dysregulation, hematology, and metabolic disorders, targeting conditions with significant unmet medical need.
About Rallybio Corp.
Rallybio Corporation is a clinical-stage biotechnology company focused on developing and commercializing therapies for patients with severe and rare diseases. The company concentrates on areas of maternal-fetal health, complement dysregulation, hematology, and metabolic disorders, targeting conditions with significant unmet medical need. Its pipeline includes RLYB212, an anti-HPA-1a antibody being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare disorder that can lead to dangerous bleeding in fetuses and newborns. Another key program is RLYB116, a differentiated inhibitor of complement component 5 (C5) intended for treatment of diseases driven by complement-mediated inflammation and tissue damage. Rallybio also advances preclinical assets such as RLYB332, a long-acting matriptase-2 antibody for diseases associated with iron overload. Operating today as a specialized player in the orphan drug and rare disease segment of the biopharmaceutical industry, Rallybio serves the healthcare and biotechnology markets from its headquarters in New Haven, Connecticut, where it was founded in 2018.
CEO Dr. Stephen Uden M.D., MBBS · 7 employees · United States · https://www.rallybio.com